Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Arsenic trioxide has been used successfully for the treatment of refractory acute promyelocytic leukemia and has shown promise in the treatment of myelodysplastic syndrome (MDS), although it is not a labeled indication. Retinoic acid syndrome is manifested by fever, dyspnea, peripheral edema, pulmonary infiltrates, and pleural and/or pericardial effusions and is typically seen in conjunction with all- trans retinoic acid therapy of acute promyelocytic leukemia. We report a case of acute lung injury and a retinoic acid syndrome-like illness in a patient who received arsenic for MDS. To our knowledge, this is the first such report, and clinicians should be aware of this potentially life-threatening complication of arsenic trioxide treatment in patients with MDS.
Hassaballa
Hesham A
HA
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rush Medical College and Rush University Medical Center, Chicago, IL 60612, USA. hhassaba@rush.edu
Lateef
Omar B
OB
Silver
Michael R
MR
Balk
Robert A
RA
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D010087:Oxides / Q000009:adverse effects* / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000139:chemically induced*
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide